Su1054 Ns3 Q80k Did Not Impact Efficacy or Treatment-Emergent Resistance Patterns in HCV Genotype-1-Infected Patients Receiving Faldaprevir Plus Pegylated Interferon/Ribavirin in Three Phase III Trials

✍ Scribed by Berger, Kristi; Sarrazin, Christoph; Ferenci, Peter; Jensen, Donald M.; Jacobson, Ira M.; Stern, Jerry O.; Quinson, Anne-Marie; Scherer, Joseph; Kukolj, George

• Book ID: 122228269
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 396 KB
• Volume: 146
• Category: Article
• ISSN: 0016-5085
• DOI: 10.1016/S0016-5085(14)63545-9